ArticleOncotarget2012
Circulating tumor-derived mutant mitochondrial DNA: a predictive biomarker of clinical prognosis in human squamous cell carcinoma.
Article in Oncotarget, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 39 citations in OpenAlex.
- Article
- Mitochondrial DNA mutations and intercellular mitochondrial transfer in cancer: mechanisms, biological effects, and clinical potential.Biomarker research · 2026Review
- The significance of mitochondrial DNA changes during the onset and progression of head and neck squamous cell carcinoma.Future oncology (London, England) · 2026Review
- Liquid biopsies based on cell-free DNA as a potential biomarker in head and neck cancer.The Japanese dental science review · 2023Review
- The changing face of circulating tumor DNA (ctDNA) profiling: Factors that shape the landscape of methodologies, technologies, and commercialization.Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V · 2023Article
- New Perspectives on the Importance of Cell-Free DNA Biology.Diagnostics (Basel, Switzerland) · 2022Review
- Article
- NGS-based accurate and efficient detection of circulating cell-free mitochondrial DNA in cancer patients.Molecular therapy. Nucleic acids · 2021Article
- Circulating Cell-Free DNA in Breast Cancer: Searching for Hidden Information towards Precision Medicine.Cancers · 2021Review
- Profiling of Mitochondrial DNA Heteroplasmy in a Prospective Oral Squamous Cell Carcinoma Study.Cancers · 2020Article
- Machine learning can accelerate discovery and application of cyber-molecular cancer diagnostics.Journal of medical artificial intelligence · 2020Article
- Tumor-Specific Mitochondrial DNA Variants Are Rarely Detected in Cell-Free DNA.Neoplasia (New York, N.Y.) · 2018Article
- Human papilloma virus: Apprehending the link with carcinogenesis and unveiling new research avenues (Review).International journal of oncology · 2018Review
- Origins, structures, and functions of circulating DNA in oncology.Cancer metastasis reviews · 2016Review
- From Normal Skin to Squamous Cell Carcinoma: A Quest for Novel Biomarkers.Disease markers · 2016Review
- ANGPTL3 is a novel biomarker as it activates ERK/MAPK pathway in oral cancer.Cancer medicine · 2015Article
- Impact of somatic mutations in the D-loop of mitochondrial DNA on the survival of oral squamous cell carcinoma patients.PloS one · 2015Article
- Enrichment of circulating melanoma cells (CMCs) using negative selection from patients with metastatic melanoma.Oncotarget · 2014Article
- The mitochondrial ATPase6 gene is more susceptible to mutation than the ATPase8 gene in breast cancer patients.Cancer cell international · 2014Article
- Article
Corrections and comments
- Commented on by
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While circulating tumor-derived molecules have been identified in a variety of malignant tumors, it is sometimes difficult to detect the molecular targets due to the lower serum concentration. We report that evaluation of circulating tumor-derived mitochondrial DNA (mtDNA) seems to have novel efficiency for detecting tumoral micrometastasis. In murine xenografting human oral cancer cells, human mtDNAs could be quantitatively detected from multiple organs and blood samples whereas human nucleic DNAs could not. We also determined if this mtDNA blood test was relevant for patients with oral cancer with no histologic evidence of tumoral cells in their surgical margins. For this, mtDNA from normal and tumorous tissues and serum mtDNA obtained pre and postoperatively was examined at three different regions including the displacement loop, 12S-rRNA, and 16S-rRNA. All non-recurring patients had significantly higher amounts of mutant mtDNAs in the tumoral tissues compared with the non-recurring group. More importantly, on the blood test with the cut-off point by receiver operating characteristic (ROC) curve analysis, while the vast majority of serum mtDNA samples obtained postoperatively in the recurring cases maintained significantly higher amounts of mutant mtDNAs, the non-recurring cases did not, and they showed good prognosis. This is the first report of this approach for managing patients after resection of oral tumors, and may have substantial diagnostic potential for other tumoral types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.